Publications by authors named "Joy Ho"

Claim this Profile
F
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Richard T Maziarz, Michael R Bishop, Constantine S Tam, Peter Borchmann, Nina Worel, Harald Holte, P Joy Ho, Monalisa Ghosh

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, P Joy Ho, Douglas Joshua, Nicholas Weber

Intern Med J· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
María-Victoria Mateos, Suzanne Trudel, Hang Quach, Paweł Robak, Meral Beksac, P Joy Ho, Xiaoou L Zhou, Pralay Mukhopadhyay

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia.
Georgia McCaughan, Hayley Beer, Christian Bryant, P Joy Ho, Tracy King, Nicholas Weber

Intern Med J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR).
Jian Li, Yayehirad Melsew, Cameron Wellard, Elizabeth M Moore, P Joy Ho

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of sickle cell disease in Australia.
Steve Nwokeocha, Helen E Haysom, Cameron Wellard, Tracy Roberts, Mwayi Kachapila, P Joy Ho

Intern Med J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robotic Surgery: Advancements and Applications of Robotic Surgery in Craniomaxillofacial Surgery.
Jasmine O Y Ho, Francesco M G Riva

Oral Maxillofac Surg Clin North Am· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Vania Hungria, Marek Hus, ChengCheng Fu, Vera Zherebtsova, Christopher Ward, P Joy Ho

Lancet Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Pralay Mukhopadhyay

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry.
Sarah Zhao, Cameron Wellard, Elizabeth M Moore, Andrew Spencer, Hang Quach, P Joy Ho

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new era in myeloma: the advent of chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies.
P Joy Ho, Eric W Li

Intern Med J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More Therapies.
Edward Abadir, Rebecca Wayte, Wenlong Li, Sachin Gupta, Shihong Yang, P Joy Ho

Transplant Cell Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal, P Joy Ho, Thomas G Martin

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.
Maria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, Thomas D Coates, Raffaella Origa, Hong-Keng Liew, P Joy Ho, Natalia Holot

Lancet Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma.
Michael Dickinson, Nicole O'Leary, Nada Hamad, Tara Cochrane, P Joy Ho, David Bishop

Intern Med J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myelomareactive CD8 T cells are shared between blood and marrow.
James Favaloro, Christian E Bryant, Edward Abadir, Samuel Gardiner, Shihong Yang, P Joy Ho

Haematologica· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Swaminathan P Iyer, R Alejandro Sica, P Joy Ho, Anca Prica, Jasmine Zain, Michael S Khodadoust, Steven M Horwitz

Lancet Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia.
P Joy Ho, Hang Quach, M Hasib Sidiqi, Cindy H Lee, Jason Butler

Front Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P Joy Ho

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies.
Eric Wenlong Li, Esther Jones, Christian Bryant, Tracy King, Dipti Talaulikar, Shir Jing Ho, P Joy Ho

Eur J Haematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
P Joy Ho, Elizabeth Moore, Cameron Wellard, Hang Quach, Hilary Blacklock

Br J Haematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Yi Lin, Lugui Qiu, Saad Usmani, Chng Wee Joo, Luciano Costa, P Joy Ho

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Xiangdong Zhou, Maureen Nichols

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in immunoglobulin use and impact on survival in myeloma.
Khai Li Chai, Cameron Wellard, Ltp Thao, Naomi Aoki, Elizabeth M Moore, P Joy Ho, Jay Hocking

EJHaem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.
Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Nicholas Weber, P Joy Ho, Noemi Horvath

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis